Clinical Trials Browser

Thyroid Carcinoma, Anaplastic × cemiplimab × 1 year × Clear all

NCT07470489 2026-04-16

Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer

Phase 2 Not yet recruiting

EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT06902376 2025-11-05

NEO-COMBATXL

Phase 1 Recruiting

EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic